Biotech Startups
9,603 companies tagged Biotech, with their investors and founders.
Cime Therapeutics is developing a chemistry-first drug discovery platform that combines automation, AI/ML, and synthetic chemistry to make molecules faster and more cost-effectively. The platform integrates the synthesis and screening stages to accelerate the Design-Make-Test-Analyze cycle in pharmaceutical discovery.
3 investors
City Therapeutics develops RNAi-based medicines targeting rare, specialty, and prevalent diseases using engineered trigger molecules and precision delivery ligands. The company aims to expand RNAi therapeutics beyond liver targeting to additional cell and tissue types.
3 investors
Clarametyx develops novel immune-enabling therapeutics targeting bacterial biofilms to modify disease progression in patients with chronic respiratory diseases.
3 investors
Clasp Therapeutics develops off-the-shelf precision T cell engagers (its proprietary pHLΠre molecules) that target mutant peptide-HLA complexes displayed on cancer cells, directing T cells to destroy tumors carrying common driver mutations such as KRas. The immuno-oncology company is running a Phase 1 trial (GUARDIAN-101) of its lead candidate CLSP-1025 for hard-to-treat cancers.
3 investors
Cleara Biotech is a biopharmaceutical R&D company developing peptide-based therapies that selectively eliminate cells with impaired p53 signaling, targeting cancer and chronic diseases. Its lead development candidates, CL04177 and CL04183, aim to induce apoptosis in cancer cells with mutant or impaired p53, with preclinical work in metastatic colon cancer and triple-negative breast cancer.
3 investors
Clearside Biomedical is an intellectual property holding, investment, and commercialization company focused on its suprachoroidal space (SCS) ocular drug-delivery platform and microinjector technology. Following its emergence from Chapter 11 in 2026, it works to rehabilitate, use, and monetize its retained intellectual property.
3 investors
3 investors
Clerio Vision is a development-stage medical device company developing LIRIC, a femtosecond laser technology that changes the refractive index of lens materials or corneal tissue without cutting or removing tissue. It applies this platform across four ophthalmic areasβmultifocal contact lenses, myopia control lenses, post-implant intraocular lens adjustment, and incisionless laser vision correctionβfor patients with presbyopia, myopia, and other refractive errors.
3 investors
ClinChoice operates a network of investigator sites that participate in clinical studies to support drug and device development. The platform connects research sites with clinical trial opportunities and commercialization support.
3 investors
Caidya is a contract research organization (CRO) that provides scientific, medical, and operational support for clinical development and cross-border clinical trials. It focuses on managing complex trials and delivering clinical data to support decision-making for drug developers.
3 investors
Collate builds AI-native software to automate documentation workflows across drug development and commercialization for life sciences companies. The platform uses machine learning to reduce manual paperwork so research and commercial teams can focus on advancing their core work.
3 investors
Colorifix uses engineered microorganisms to produce, deposit, and fix dyes on textiles through a biological fermentation process, aiming to reduce the environmental impact of textile dyeing. It develops and manufactures bioreactors and fermentation media for textile industry customers.
3 investors
3 investors
Concarlo Therapeutics develops cancer therapeutics that target CDK4/6-driven cell proliferation and CDK2-driven resistance, focusing on improving outcomes for cancer patients through novel approaches in p27 biology.
3 investors
Condor is an enterprise-grade financial cloud platform purpose-built for accounting, finance, clinical operations, and FP&A teams in biopharma companies. The platform automates financial workflows and integrates with existing systems to accelerate clinical trial execution and bring therapies to patients faster.
3 investors
Congruence is a drug discovery company that applies protein dynamics, biophysics, machine learning, and computational chemistry to model proteins in their full dynamic state and predict disease correction in silico. It uses these computational methods to identify and design therapeutics.
3 investors
Connect Biopharm develops next-generation therapeutics for inflammatory diseases. The company focuses on drug development aimed at treating patients with inflammatory conditions.
3 investors
3 investors
Contineum Therapeutics develops therapies targeting conditions at the intersection of inflammatory and fibrotic diseases, including a candidate for idiopathic pulmonary fibrosis (IPF) and chronic pain, and a candidate for major depressive disorder (MDD) developed with Janssen Pharmaceutica. It is a clinical-stage biopharmaceutical company focused on patients with limited treatment options.
3 investors
Convelo Therapeutics develops remyelination-enhancing therapies that target the central nervous system's myelination pathway to repair nerve damage in people with multiple sclerosis. The company operates a drug discovery platform focused on neurological disorders and originated from research at Case Western Reserve University.
3 investors
Core Biogenesis is a French biotech that uses an oleosome fusion platform to grow active peptides and proteins (such as EGF and FGF-2) inside camelina seeds, producing formulation-ready topical delivery carriers for skin and scalp. It supplies these recombinant protein actives to the cosmetics and personal care industry, serving formulators, R&D teams, and brands.
3 investors
3 investors
Corvus is a clinical-stage biopharmaceutical company developing therapies for immune diseases and cancer. Its lead program, soquelitinib, is an oral therapy that selectively inhibits ITK to modulate immune system signaling pathways.
3 investors
Cradle uses AI to help scientists design and engineer proteins, decoding and rewriting biology to develop new food sources, materials, and therapeutics. It serves research scientists and offers models validated in its own lab before delivery to customers.
3 investors